摘要
目的探讨microRNA-221(miR-221)在神经胶质瘤患者脑脊液中的水平及其临床意义。方法采用实时荧光定量聚合酶链反应(real-time PCR)检测49例神经胶质瘤患者及40例健康人脑脊液中miR-221的水平,分析miR-221与病理分级间的关系。结果神经胶质瘤患者脑脊液中miR-221水平与对照组相比明显升高,差异具有统计学意义(0.68±0.10 vs0.47±0.07,P<0.01);神经胶质瘤患者脑脊液中miR-221水平随着病理分级增加有所增高,但差异没有统计学意义(P>0.05)。结论神经胶质瘤患者脑脊液中miR-21水平增高,miR-221可能参与了胶质瘤的发生、发展过程。
Objective To explore the levels of microRNA-221（miR-221）in cerebrospinal fluid and its clinical significance in patients with glioma.Methods In 38 patients with glioma and 40 normal controls,the levels of miR-221 in cerebrospinal fluid were measured by real-time PCR.The relationship between miR-221 and pathological grade was analyzed.Results The level of miR-221 in cerebrospinal fluid of glioma patients was statistically higher than that in the controls（0.68±0.10 vs 0.47±0.07,P0.01）.The levels of miR-221 increased with the increase of pathological grade,but there was no significant difference（P0.05）.Conclusion The levels of miR-221 are elevated in cerebrospinal fluid of glioma patients.The miR-221 may participate in the occurrence and development of glioma.
出处
《山西医科大学学报》
CAS
2013年第2期142-144,共3页
Journal of Shanxi Medical University
作者简介
陈欣，男，1976—08生，在读硕士，主治医师，E—mail：zhaobinjietougao@126．com．
